Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment